US 12,257,236 B2
Oral formulations of metronidazole and methods of treating an infection using same
Bernard J. Guarino, Jr., Lodi, NJ (US); Jamie L. Doran, Guelph (CA); Zorana Radovic, Laval (CA); Kevin Sullivan, Halifax (CA); and Armand Louis Balboni, Waterford, VA (US)
Assigned to Appili Therapeutics Inc., Halifax (CA)
Filed by Appili Therapeutics Inc., Halifax (CA)
Filed on Nov. 30, 2022, as Appl. No. 18/072,154.
Application 18/072,154 is a continuation of application No. 16/959,536, granted, now 11,541,035, previously published as PCT/CA2019/050053, filed on Jan. 16, 2019.
Claims priority of provisional application 62/617,703, filed on Jan. 16, 2018.
Prior Publication US 2023/0086660 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4164 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 47/46 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/4164 (2013.01) [A61K 9/0053 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 47/46 (2013.01); A61P 31/04 (2018.01)] 21 Claims
 
1. An oral pharmaceutical liquid suspension comprising a) metronidazole or a pharmaceutically acceptable salt thereof; and b) magnesium aluminum silicate, wherein the magnesium aluminum silicate is a natural product.
 
2. An oral pharmaceutical liquid suspension comprising a) metronidazole or a pharmaceutically acceptable salt thereof; b) magnesium aluminum silicate; and c) and at least one flavoring agent, wherein the magnesium aluminum silicate is a natural product.
 
17. An oral pharmaceutical liquid suspension comprising: metronidazole, sucrose, glycerin, purified water, magnesium aluminum silicate, microcrystalline cellulose, sucralose, sodium phosphate, one or more preservatives, strawberry flavoring agent and peppermint flavoring agent, wherein the magnesium aluminum silicate is a natural product.
 
18. A method of treating an infection in a patient, said method comprising the step of administering to the patient an effective amount of an oral pharmaceutical liquid suspension comprising:
a) metronidazole or a pharmaceutically acceptable salt thereof and magnesium aluminum silicate; or
b) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and at least one flavoring agent;
wherein the magnesium aluminum silicate is a natural product.